[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:glioma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":306,"states":319},"Glioma",80,66,[8,16,23,29,35,42,49,55,61,67,73,79,85,90,96,102,108,114,120,125,131,137,143,149,155,161,167,173,179,185,191,197,203,209,214,220,226,232,238,244,250,256,261,266,272,277,282,288,294,300],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07025226","Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease",[12],"Early Phase 1","RECRUITING","2026-08-26T02:16:52.995882Z","2026-07-05T05:32:16.729507Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06964737","Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas",[20],"Phase 1","2026-08-26T02:15:24.145250Z","2026-07-05T05:32:16.722257Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07541781","Sitagliptin in Recurrent\u002FProgressive Grade 4 Glioma",[20],"2026-08-26T02:18:51.009190Z","2026-07-05T05:32:16.685541Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06410248","Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma",[20],"2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.489352Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT05859334","Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment",[39],"Phase 2","2026-08-03T01:55:52.940420Z","2026-05-05T02:43:29.734336Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT07539441","A Study of Mirdametinib in People With Central Nervous System Tumors",[46],"Phase 1\u002FPhase 2","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.284240Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06610682","A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:29.161550Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06397560","PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial",[],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.564628Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03922555","ASTX727 in Recurrent\u002FProgressive Non-enhancing IDH Mutant Gliomas",[20],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.502498Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05310448","Tumor Treating Fields for the Treatment of Brainstem Gliomas",[],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:28.502482Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06011109","Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab",[46],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:28.495620Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04547777","Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma",[20],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:28.286836Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":47,"content_modified":89},"NCT06482905","Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.",[20],"2026-05-05T02:43:28.000760Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT04181684","LITT Followed by Hypofractionated RT for Recurrent Gliomas",[],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:27.950818Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05804227","Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas",[12],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:27.946570Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT03728673","A Study Utilizing Escitalopram in Glioma Patients",[39],"2026-08-26T02:16:27.227548Z","2026-05-05T02:43:27.769197Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT04623931","Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas",[39],"2026-08-26T02:19:17.380174Z","2026-05-05T02:43:27.621794Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07074756","A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma",[],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:27.606543Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":83,"content_modified":124},"NCT05460507","Safety & Efficacy\u002FTolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment",[20],"2026-05-05T02:43:27.512450Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT05188508","Pembrolizumab, Olaparib, and Temozolomide for People With Glioma",[39],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.089223Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT01906385","Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)",[46],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.056529Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT04699773","LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)",[],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:26.907699Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT06636162","Window of Opportunity Study of DSP-0390 in Gliomas",[12],"2026-08-26T02:19:23.493898Z","2026-05-05T02:35:31.909401Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT07464925","A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma",[20],"2026-08-26T02:19:20.945539Z","2026-05-05T02:35:31.905066Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT02800486","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed\u002FRefractory GBM, AA, and AOA",[39],"2026-08-26T02:15:25.633039Z","2026-05-05T02:43:28.816336Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":27,"content_modified":166},"NCT05303519","SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)",[165],"Phase 3","2026-05-05T02:43:27.742731Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[20],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06132685","Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial",[39],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:26.663660Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[39],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:28.903254Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[46],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT05355701","A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.",[20],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.510653Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT06161519","PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications",[46],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:28.398018Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":27,"content_modified":213},"NCT05538130","A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors",[20],"2026-05-05T02:43:27.578185Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT02390752","Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.488578Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT03739411","Hyperpolarized Imaging in Diagnosing Participants With Glioma",[20],"2026-08-26T02:16:22.235886Z","2026-07-05T05:32:16.771120Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT06444412","An Investigational Scan (Ga-68 PSMA-11 PET\u002FCT) for Detection of Disease Recurrence or Progression in Patients With Glioma",[39],"2026-08-26T02:18:17.007929Z","2026-07-05T05:32:16.753250Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT04373720","MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas",[],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.503032Z",{"nct_id":239,"title":240,"phases":241,"status":13,"updated_at":242,"content_modified":243},"NCT05212272","MRI in High-Grade Glioma Patients Undergoing Chemoradiation",[],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:28.102949Z",{"nct_id":245,"title":246,"phases":247,"status":13,"updated_at":248,"content_modified":249},"NCT04540107","Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma",[20],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:27.751753Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT04772456","Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas",[20],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:27.750220Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":159,"content_modified":260},"NCT00870129","Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors",[],"2026-05-05T02:43:27.428186Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":183,"content_modified":265},"NCT07063693","ABY-029 Glioma Trial",[20],"2026-05-05T02:43:26.983175Z",{"nct_id":267,"title":268,"phases":269,"status":13,"updated_at":270,"content_modified":271},"NCT03684109","Non-invasive Glioma Characterization Through Molecular Imaging",[],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:26.757567Z",{"nct_id":273,"title":274,"phases":275,"status":13,"updated_at":83,"content_modified":276},"NCT04135807","Implantable Microdevice In Primary Brain Tumors",[12],"2026-05-05T02:43:26.708030Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":65,"content_modified":281},"NCT06942104","Imaging of Solid Tumors Using 18F-TRX",[20],"2026-05-05T02:43:28.487264Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT06650163","Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors",[20],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.572146Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT05139277","Evaluation of the CONVIVO System",[],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:29.047316Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers",[20],"2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.547796Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT06101069","Development of MRF for Characterization of Brain Tumors After Radiotherapy",[],"2026-08-26T02:16:12.203827Z","2026-05-05T02:35:31.765025Z",[307,311,315],{"biomarker":308,"count":309,"slug":310},"IDH1 wt Allele",8,"idh1-wt-allele",{"biomarker":312,"count":313,"slug":314},"IDH1 Gene",5,"idh1-gene",{"biomarker":316,"count":317,"slug":318},"BRAF Gene",4,"braf-gene",[320,324,328,332,335,339,343,347,350,353,357,360,363,366,369,372,375,378,381,385,388,391,394,397],{"state":321,"count":322,"slug":323},"New York",20,"new-york",{"state":325,"count":326,"slug":327},"Texas",16,"texas",{"state":329,"count":330,"slug":331},"California",13,"california",{"state":333,"count":330,"slug":334},"Florida","florida",{"state":336,"count":337,"slug":338},"Massachusetts",12,"massachusetts",{"state":340,"count":341,"slug":342},"Minnesota",10,"minnesota",{"state":344,"count":345,"slug":346},"New Jersey",9,"new-jersey",{"state":348,"count":309,"slug":349},"Maryland","maryland",{"state":351,"count":309,"slug":352},"Ohio","ohio",{"state":354,"count":355,"slug":356},"Colorado",6,"colorado",{"state":358,"count":355,"slug":359},"Illinois","illinois",{"state":361,"count":355,"slug":362},"Tennessee","tennessee",{"state":364,"count":313,"slug":365},"Connecticut","connecticut",{"state":367,"count":313,"slug":368},"Missouri","missouri",{"state":370,"count":313,"slug":371},"North Carolina","north-carolina",{"state":373,"count":313,"slug":374},"Pennsylvania","pennsylvania",{"state":376,"count":317,"slug":377},"Michigan","michigan",{"state":379,"count":317,"slug":380},"Washington","washington",{"state":382,"count":383,"slug":384},"Alabama",3,"alabama",{"state":386,"count":383,"slug":387},"Georgia","georgia",{"state":389,"count":383,"slug":390},"Nebraska","nebraska",{"state":392,"count":383,"slug":393},"Oregon","oregon",{"state":395,"count":383,"slug":396},"Utah","utah",{"state":398,"count":383,"slug":399},"Virginia","virginia"]